Biotechnology News

De tilbagekøbte aktier vil blive annulleret, forudsat godkendelse fra aktionærerne KØBENHAVN, Danmark, 21. august 2026 – Bavarian Nordic A/S (OMX: BAVA) offentliggjorde i dag hensigt om at lancere et...

Guidance upgrade reflects upper end of previous guided revenue range and an improved EBITDA margin COPENHAGEN, Denmark, August 21, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced an upgrade of...

Opjusteringen afspejler den øvre ende af det tidligere udmeldte omsætningsinterval samt en forbedret EBITDA-margin KØBENHAVN, Danmark, 21. august 2026 – Bavarian Nordic A/S (OMX: BAVA) meddelte i...

WALTHAM, Mass., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically...

APTN-101’s unique mechanism of action is designed to overcome the limitations for effective treatment of malignant brain tumors by enhancing the transport of therapies across the blood-brain barrier...

Polyrizon completes contracting with all five U.S. clinical sites and advances its NASARIX™ study toward enrollment of 120 patients Raanana, Israel, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Polyrizon...

SARASOTA, Fla., Aug. 20, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) ("INVO Fertility" or the "Company"), a healthcare fertility company focused on the establishment, acquisition,...

SOLANA BEACH, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating...

Debt and liabilities holders have executed $10.7 million of Series A Convertible Exchange Agreements; of which $4.57 million was converted into Series A Convertible Preferred Stock Sufficient working...

Designation reflects serious unmet need in idiopathic pulmonary fibrosis (IPF), where approved therapies slow but do not halt disease progressionActively enrolling patients in the RENEW Phase 2 trial...